Industry Report: Healthcare Report Q1 2025 [Cassel Selpeter]

Key Report Highlights

• Market Uncertainty Dampens M&A and Funding Activity
  Despite early optimism in 2025, the healthcare and biotech sectors are facing significant headwinds. VC funding has slowed, IPO activity is minimal, and M&A deals have softened, particularly in biotech. Many companies are relying on licensing transactions instead of full acquisitions to manage risk in a volatile climate.
• Tariffs, Reshoring, and Staffing Shortages Pressure Biopharma
  Tariffs, long equipment lead times, and workforce shortages constrain proposed reshoring of drug manufacturing to the U.S.. A lack of skilled chemists and engineers further complicates reshoring efforts, especially as many current tools and talent are sourced internationally.
• Federal Research Cuts Threaten Innovation Pipeline
  Budget cuts to NIH, CDC, and FDA have triggered a dramatic reduction in research grants and fellowships, threatening the “farm system” that feeds biopharma innovation. Entire NIH disciplines may disappear, while FDA staffing losses are already delaying drug and device approvals.
• Brain Drain and Shutdowns Reshape Industry Landscape
  Numerous biotech companies are scaling back operations or shutting down entirely due to lack of capital. This has led to significant layoffs and potential long-term “brain drain” from U.S. life sciences hubs like Boston and San Francisco, as talent either exits the industry or moves abroad.
• Diagnostics and Telehealth Show Resilience
  While capital markets remain tight, diagnostics/lab testing and telehealth continue to attract investor interest. Companies like Quest Diagnostics and Veradigm show strong EBITDA performance, and many providers are leaning into tech-enabled models that emphasize efficiency and remote care delivery.

Cassel Salpeter & Co. is a boutique investment banking firm providing independent, conflict-free advisory services to middle-market and emerging growth companies across the U.S. Headquartered in Miami and founded in 2010, the firm specializes in mergers and acquisitions, capital raising, fairness opinions, restructurings, and board advisory services.

Serving companies typically generating up to $250 million in revenue, Cassel Salpeter operates across diverse sectors, including healthcare, technology, manufacturing, consumer products, and business services. The firm is particularly active in advising founder-led and family-owned businesses, as well as private equity portfolio companies, on both buy-side and sell-side mandates.

Known for its senior-led execution model and deep industry knowledge, Cassel Salpeter delivers tailored, high-touch advisory built around long-term client relationships. Securities are offered through DealForce Capital Markets LLC, a member of FINRA and SIPC.

Interested in sharing your industry reports? Contact: kaitlinn.thatcher@axial.net